Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Glycopyrrolate
7 Limited Use · 3 not a benefit
Glycopyrrolate Injection · DIN 02382857 · 0.2 mg/mL · injection solution
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection · DIN 02382857
Manufacturer: Omega Laboratories Ltd.; listing date 2015-03-31
Health Canada: Marketed since 2012-06-29 · brand GLYCOPYRROLATE INJECTION · ATC A03AB02 GLYCOPYRRONIUM · form Liquid · route Intramuscular, Intravenous · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Omega laboratories limited · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordGlycopyrrolate Injection: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02382857)
Source record
DIN 02382857: Glycopyrrolate Injection
Raw flags: sec12=Y, sec3=Y
Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id OMG
Source form: Inj Sol; strength: 0.2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02382857
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86866
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473879 · $2.7825
Robinul · DIN 02043610 · not recorded
Sandoz Glycopyrrolate · DIN 02039508 · $2.7825
Shortage status: shortage reported ended September 3, 2026 (report last updated September 3, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02382857
Shortage record checked October 6, 2026
Glycopyrrolate Injection USP · DIN 02473879 · 0.2 mg/mL · injection solution
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02473879
Manufacturer: Sterimax Inc.; listing date 2022-08-31
Health Canada: Marketed since 2021-05-26 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 0.2 MG/1ML · company Sterimax inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordGlycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473879)
Source record
DIN 02473879: Glycopyrrolate Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id STE
Source form: Inj Sol; strength: 0.2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473879
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96360
Interchangeable products
Glycopyrrolate Injection · DIN 02382857 · $2.7825
Robinul · DIN 02043610 · not recorded
Sandoz Glycopyrrolate · DIN 02039508 · $2.7825
Shortage status: resolved shortage (ended March 11, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473879
Shortage record checked October 6, 2026
Sandoz Glycopyrrolate · DIN 02039508 · 0.2 mg/mL · injection solution
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Sandoz Glycopyrrolate · DIN 02039508
Manufacturer: Sandoz Canada Inc.; listing date 2017-07-31
Health Canada: Marketed since 2005-09-21 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Sandoz canada incorporated · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Glycopyrrolate: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02039508)
Source record
DIN 02039508: Sandoz Glycopyrrolate
Raw flags: sec12=Y, sec3=Y
Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id SDZ
Source form: Inj Sol; strength: 0.2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02039508
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14577
Interchangeable products
Glycopyrrolate Injection · DIN 02382857 · $2.7825
Glycopyrrolate Injection USP · DIN 02473879 · $2.7825
Robinul · DIN 02043610 · not recorded
Shortage status: resolved shortage (ended March 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02039508
Shortage record checked October 6, 2026
Glycopyrrolate Injection USP · DIN 02473895 · 0.4 mg/2 mL · injection solution (Preservative Free)
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02473895
Manufacturer: Sterimax Inc.; listing date 2022-08-31
Health Canada: Marketed since 2021-05-26 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 0.4 MG/2ML · company Sterimax inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordGlycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473895)
Source record
DIN 02473895: Glycopyrrolate Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 120808014; group id 214; item number 0389; lccId 00288; manufacturer id STE
Source form: Inj Sol (Preservative Free); strength: 0.4mg/2mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473895
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96361
Interchangeable products
Glycopyrrolate Injection USP · DIN 02513749 · $2.7825
Robinul · DIN 09858163 · not recorded
Shortage status: resolved shortage (ended March 11, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473895
Shortage record checked October 6, 2026
Glycopyrrolate Injection USP · DIN 02513749 · 0.4 mg/2 mL · injection solution (Preservative Free)
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02513749
Manufacturer: Jamp Pharma Corporation; listing date 2024-08-30
Health Canada: Marketed since 2022-04-01 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intramuscular, Intravenous · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Jamp pharma corporation · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordGlycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02513749)
Source record
DIN 02513749: Glycopyrrolate Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 120808014; group id 214; item number 0389; lccId 00288; manufacturer id JPC
Source form: Inj Sol (Preservative Free); strength: 0.4mg/2mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02513749
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100293
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473895 · $2.7825
Robinul · DIN 09858163 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02513749
Shortage record checked October 6, 2026
Glycopyrrolate Injection USP · DIN 02473887 · 4 mg/20 mL · injection solution (With Preservative)
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02473887
Manufacturer: Sterimax Inc.; listing date 2022-08-31
Health Canada: Marketed since 2021-05-26 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 4 MG/20ML · company Sterimax inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordGlycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473887)
Source record
DIN 02473887: Glycopyrrolate Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 120808015; group id 214; item number 0390; lccId 00288; manufacturer id STE
Source form: Inj Sol (With Preservative); strength: 4mg/20mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473887
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96362
Interchangeable products
Glycopyrrolate Injection USP · DIN 02532379 · $2.7825
Robinul · DIN 09858164 · not recorded
Shortage status: resolved shortage (ended May 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473887
Shortage record checked October 6, 2026
Glycopyrrolate Injection USP · DIN 02532379 · 4 mg/20 mL · injection solution (With Preservative)
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02532379
Manufacturer: Jamp Pharma Corporation; listing date 2024-03-28
Health Canada: Marketed since 2024-01-18 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intramuscular, Intravenous · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Jamp pharma corporation · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordGlycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02532379)
Source record
DIN 02532379: Glycopyrrolate Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 120808015; group id 214; item number 0390; lccId 00288; manufacturer id JPC
Source form: Inj Sol (With Preservative); strength: 4mg/20mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.7825; ministry $2.7825
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02532379
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102141
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473887 · $2.7825
Robinul · DIN 09858164 · not recorded
Shortage status: resolved shortage (ended April 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02532379
Shortage record checked October 6, 2026
Robinul · PIN 09858163 · 0.4 mg/2 mL · injection solution (Preservative Free)
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchOntario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Robinul · DIN 09858163
Manufacturer: Wyeth-Ayerst Canada Inc.; listing date 2022-08-31
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)Robinul: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858163)
Source record
DIN 09858163: Robinul
Raw flags: notABenefit=Y, sec3=Y
Item: 120808014; group id 214; item number 0389; lccId 00288; manufacturer id WYA
Source form: Inj Sol (Preservative Free); strength: 0.4mg/2mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858163
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473895 · $2.7825
Glycopyrrolate Injection USP · DIN 02513749 · $2.7825
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858163
Shortage record checked October 6, 2026
Robinul · PIN 09858164 · 4 mg/20 mL · injection solution (With Preservative)
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchOntario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Robinul · DIN 09858164
Manufacturer: Wyeth-Ayerst Canada Inc.; listing date 2022-08-31
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)Robinul: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858164)
Source record
DIN 09858164: Robinul
Raw flags: notABenefit=Y, sec3=Y
Item: 120808015; group id 214; item number 0390; lccId 00288; manufacturer id WYA
Source form: Inj Sol (With Preservative); strength: 4mg/20mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858164
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473887 · $2.7825
Glycopyrrolate Injection USP · DIN 02532379 · $2.7825
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858164
Shortage record checked October 6, 2026
Robinul · DIN 02043610 · 0.2 mg/mL · injection solution
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-03-07 — choose a marketed DIN from the same-category list.Discontinued March 7, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-03-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-03-07 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Robinul · DIN 02043610
Manufacturer: Wyeth-Ayerst Canada Inc.; listing date 2015-03-31
Health Canada: Cancelled post market since 2000-03-07 · brand ROBINUL 0.2MG/ML LIQ INJ · ATC A03AB02 GLYCOPYRRONIUM · form Liquid · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE .2 MG/ML · company Wyeth-ayerst canada inc. · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product recordRobinul: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02043610)
Source record
DIN 02043610: Robinul
Raw flags: notABenefit=Y, sec3=Y
Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id WYA
Source form: Inj Sol; strength: 0.2mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02043610
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15891
Interchangeable products
Glycopyrrolate Injection · DIN 02382857 · $2.7825
Glycopyrrolate Injection USP · DIN 02473879 · $2.7825
Sandoz Glycopyrrolate · DIN 02039508 · $2.7825
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02043610
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 7, 2000 — choose a marketed DIN from the same-category list.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old.
(ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered.
(ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity
(ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described.
(ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table.
(ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year)
(ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible)
(ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2.
(ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old."
(ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds."
(ontario.ca, August 18, 2026 ↗)Other review policies
For Robinul: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
Ontario source; updated September 15, 2026
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.
Ontario source; updated September 15, 2026